The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genome-wide association study to reveal novel germline markers of melanoma survival.
 
Vylyny Chat
No Relationships to Disclose
 
Robert Ferguson
No Relationships to Disclose
 
Leah Morales
No Relationships to Disclose
 
Una Moran
No Relationships to Disclose
 
Min Jae Kim
No Relationships to Disclose
 
Matija Snuderl
No Relationships to Disclose
 
Iman Osman
No Relationships to Disclose
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; CytomX Therapeutics; Neximmune; Protean Biodiagnostics
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncosec; Regeneron; Roche; Sellas Life Sciences; Takeda; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; Novartis; Oncosec; Protean Biodiagnostics; Roche; Sellas Life Sciences; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Novartis; Roche
 
Tomas Kirchhoff
No Relationships to Disclose